Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone and free fatty acid-induced insulin resistance in obese patients with type 2 diabetes
NL-OMON25285Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial in type 2 diabetes mellitus (T2DM) comparing Pioglitazone with Placebo (2 arms). Primary endpoints: Basal glucose production, Plasma free fatty acids and 2 more. Started Sep 2002; status: active, not recruiting.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON25285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25285.